Figure 1 (Azithromycin 01)
Azithromycin Injection, Powder, Lyophilized, For Solution
Product Images NDC 0409-0144
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Azithromycin (NDC 0409-0144). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Azithromycin 02)
Figure 3 (Azithromycin 03)
Figure 4 (Azithromycin 04)
Figure 5 (Azithromycin 05)
Figure 6 (Azithromycin 06)
Figure 7 (Azithromycin 07)
Azithromycin Structural Formula (Azithromycin 08)
Hospira Logo (Azithromycin 09)
Principal Display Panel (500 mg Vial Label)
This is a description of a medication with the NDC code 0409-0144-2T containing azithromycin monohydrate. The medication is in the form of an ADD-Vantage® vial for single use, equivalent to 500 mg of azithromycin. It also contains anhydrous citric acid and sodium hydroxide for pH adjustment. Detailed instructions for use are provided in the package insert for assembling the vial with a flexible diluent container. The diluted solution after preparation contains 2 mg/mL of Azithromycin. It is recommended to store the vial at 20 to 25°C before dilution and to keep the diluted solution stable for 24 hours at room temperature or 7 days under refrigeration. The medication is for intravenous use, and the usual dosage should be followed as per the insert. Distributed by Hospira, Inc. in Lake Forest, IL, USA.*
Principal Display Panel (500 mg Vial Tray)
This text provides information about a pharmaceutical product called Azithromycin for Injection, USP, available in single-dose ADD-Vantage vials. Each vial contains azithromycin monohydrate equivalent to 500 mg, along with other components. The vials are intended for intravenous use and must be diluted before administration. Instructions for use and storage recommendations are included. The product is distributed by Hospira, Inc., and the usual dosage information is provided in the insert.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
